08HH Stock Chart & Stats
€1.80
€0.03(1.75%)
At close: 4:00 PM EDT
€1.80
€0.03(1.75%)
Day’s Range― - ―
52-Week Range€1.66 - €3.22
Previous CloseN/A
Volume0.00
Average Volume (3M)1.21K
Market Cap
€7.32B
Enterprise Value€84.21K
Total Cash (Recent Filing)€15.29B
Total Debt (Recent Filing)€31.86B
Price to Earnings (P/E)17.6
Beta0.26
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume2,287
30 Day Avg. Volume1,211
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.79Price Target Upside54.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.16
Revenue Forecast (FY)€4.84B
Bulls Say, Bears Say
Bulls Say
Diversified Multi-segment ModelThe firm's multi-segment business—manufacturing, distribution and healthcare services—reduces reliance on any single revenue source. Over the medium term this diversification supports steadier revenue, multiple margin pools and resilience to product-specific or reimbursement shocks.
Strong Revenue Rebound And Healthy MarginsA pronounced TTM revenue recovery with robust gross margins and positive net margin signals regained commercial momentum and improved product mix. Sustained top-line growth with decent margins provides a firmer base to fund R&D, commercialization and higher-margin specialty expansion over coming months.
Operating Cash Flow Recovery And Positive FCFOperating cash flow is positive and free cash flow has returned after prior deficits, indicating operational stabilization. Improved cash generation reduces near-term refinancing risk and supports capex, working capital and strategic investments, improving durability of operations.
Bears Say
Weak Cash ConversionFCF at roughly a quarter of net income and a history of volatility means earnings do not reliably convert to cash. This weak conversion raises execution and liquidity risk for capex, dividends or M&A, and makes the company sensitive to working-capital swings and investment needs.
Moderate Leverage And Average ReturnsA debt-to-equity near 0.75 with only mid-single-digit ROE points to moderate leverage and limited capital efficiency. This combination constrains financial flexibility, increases sensitivity to interest-cost rises, and limits ability to pursue aggressive reinvestment without raising leverage.
Operating Margin PressureRelatively low EBIT margin and declining EBITDA margins suggest cost or mix pressures that could blunt profit leverage from revenue growth. Continued margin erosion would limit free cash flow expansion and reduce the durability of the recent revenue recovery absent structural cost fixes.
Shanghai Fosun Pharmaceutical (Group) Co News
08HH FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was €1.66 and its highest was €3.22 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is €7.32B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 22 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported €0.042 earnings per share for the quarter, beating the consensus estimate of €0.042 by <€0.001.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H does not currently pay dividends.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.05.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of €0.042 in its last earnings report, beating expectations of €0.042. Following the earnings report the stock price went down -0.242%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in DE:08HH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.79 (54.79% Upside)
€2.79 (54.79% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.66%
12-Months-Change
Fundamentals
Return on Equity
2.69%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
08HH Stock 12 Month Forecast
Average Price Target
€2.79
▲(54.79% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―